These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9646034)

  • 1. Expression of macrophage migration inhibitory factor in the human prostate.
    Meyer-Siegler K; Fattor RA; Hudson PB
    Diagn Mol Pathol; 1998 Feb; 7(1):44-50. PubMed ID: 9646034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer.
    Meyer-Siegler KL; Iczkowski KA; Vera PL
    BMC Cancer; 2005 Jul; 5():73. PubMed ID: 16000172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma.
    Meyer-Siegler KL; Bellino MA; Tannenbaum M
    Cancer; 2002 Mar; 94(5):1449-56. PubMed ID: 11920501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage migration inhibitory factor in the human prostate: identification and immunocytochemical localization.
    Arcuri F; del Vecchio MT; de Santi MM; Lalinga AV; Pallini V; Bini L; Bartolommei S; Parigi S; Cintorino M
    Prostate; 1999 May; 39(3):159-65. PubMed ID: 10334104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased stability of macrophage migration inhibitory factor (MIF) in DU-145 prostate cancer cells.
    Meyer-Siegler K
    J Interferon Cytokine Res; 2000 Sep; 20(9):769-78. PubMed ID: 11032396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of c-kit and kit-ligand in benign and malignant prostatic tissues.
    Simak R; Capodieci P; Cohen DW; Fair WR; Scher H; Melamed J; Drobnjak M; Heston WD; Stix U; Steiner G; Cordon-Cardo C
    Histol Histopathol; 2000 Apr; 15(2):365-74. PubMed ID: 10809354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage migration inhibitory factor in prostatic adenocarcinoma: correlation with tumor grading and combination endocrine treatment-related changes.
    del Vecchio MT; Tripodi SA; Arcuri F; Pergola L; Hako L; Vatti R; Cintorino M
    Prostate; 2000 Sep; 45(1):51-7. PubMed ID: 10960842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer.
    Eastham JA; Truong LD; Rogers E; Kattan M; Flanders KC; Scardino PT; Thompson TC
    Lab Invest; 1995 Nov; 73(5):628-35. PubMed ID: 7474936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of macrophage migration inhibitory factor in promoting benign prostatic hyperplasia epithelial cell growth by modulating COX-2 and P53 signaling.
    Song H; Shen Q; Hu S; Jin J
    Biol Open; 2020 Nov; 9(11):. PubMed ID: 33148606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases.
    Meyer-Siegler K; Hudson PB
    Urology; 1996 Sep; 48(3):448-52. PubMed ID: 8804500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gray level entropy matrix is a superior predictor than multiplex ELISA in the detection of reactive stroma and metastatic potential of high-grade prostatic adenocarcinoma.
    Jia X; Sun Y; Wang B
    IUBMB Life; 2014 Dec; 66(12):847-53. PubMed ID: 25631296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transforming growth factor beta 1 and its receptor types I and II. Comparison in human normal prostate, benign prostatic hyperplasia, and prostatic carcinoma.
    Royuela M; De Miguel MP; Bethencourt FR; Sanchez-Chapado M; Fraile B; Paniagua R
    Growth Factors; 1998; 16(2):101-10. PubMed ID: 9932228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A lectin histochemistry comparative study in human normal prostate, benign prostatic hyperplasia, and prostatic carcinoma.
    Arenas MI; Romo E; de Gaspar I; de Bethencourt FR; Sánchez-Chapado M; Fraile B; Paniagua R
    Glycoconj J; 1999 Jul; 16(7):375-82. PubMed ID: 10619710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transforming growth factor-beta 3 is expressed in nondividing basal epithelial cells in normal human prostate and benign prostatic hyperplasia, and is no longer detectable in prostate carcinoma.
    Djonov V; Ball RK; Graf S; Mottaz AE; Arnold AM; Flanders K; Studer UE; Merz VW
    Prostate; 1997 May; 31(2):103-9. PubMed ID: 9140123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Release of macrophage migration inhibitory factor by neuroendocrine-differentiated LNCaP cells sustains the proliferation and survival of prostate cancer cells.
    Tawadros T; Alonso F; Jichlinski P; Clarke N; Calandra T; Haefliger JA; Roger T
    Endocr Relat Cancer; 2013 Feb; 20(1):137-49. PubMed ID: 23207293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunohistochemical study of the prostatic tissues with monoclonal antibody against gamma-seminoprotein. Analyses of benign prostatic hyperplasia, metastatic foci from adenocarcinoma of the prostate and malignant neoplasms other than adenocarcinoma of the prostate].
    Fujino A; Shimura S; Murayama M; Ao T; Yokoyama E; Mashimo S; Ishibashi A; Koshiba K; Kuwao S
    Nihon Hinyokika Gakkai Zasshi; 1993 Mar; 84(3):527-34. PubMed ID: 7685842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrophage migration inhibitory factor increases MMP-2 activity in DU-145 prostate cells.
    Meyer-Siegler K
    Cytokine; 2000 Jul; 12(7):914-21. PubMed ID: 10880236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.
    Hahn D; Simak R; Steiner GE; Handisurya A; Susani M; Marberger M
    J Urol; 2000 Aug; 164(2):506-10. PubMed ID: 10893635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High concentrations of the macrophage migration inhibitory factor in human seminal plasma and prostatic tissues.
    Frenette G; Tremblay RR; Dubé JY; Lazure C; Lemay M
    Arch Androl; 1998; 41(3):185-93. PubMed ID: 9805147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer.
    Mariani S; Salvatori L; Basciani S; Arizzi M; Franco G; Petrangeli E; Spera G; Gnessi L
    J Urol; 2006 Jun; 175(6):2072-7; discussion 2077. PubMed ID: 16697805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.